Apellis Pharmaceuticals Inc

Overview

Apellis Pharmaceuticals Inc (Apellis) is a clinical-stage bio-pharmaceutical company which focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases through inhibition of the complement system at the level of C3 (central protein). Its pipeline product portfolio includes APL-2, a C3 inhibitor administered by intravitreal injections and subcutaneous injection for the treatment of geographic atrophy (GA), paroxysmal nocturnal hemoglobinuria (PNH), wet age-related macular degeneration (AMD), autoimmune hemolytic anemia (AIHA) and complement-dependent nephropathies. Apellis complement system activates C3 protein which enables immune responses such as opsonization, inflammation and formation of the membrane attack complex. It also conducts research on chronic therapy with a C3 inhibitor into clinical trials. The company operates with offices in the US, Ireland, Switzerland and Australia. Apellis is headquartered in Waltham, Massachusetts, the US.
Key Stats
Address
100 Fifth Avenue, WALTHAM, Massachusetts
Headquarters

United States of America

Contact

1 617 9775700

Website
apellis.com
No of Employees

445

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

APLS [NASD]

Revenue (2020)

$251 m

0% (2020 vs 2019)
Net Income (2020)

$-345 m

-13.2% (2020 vs 2019)
Net Profit Margin

-138 %

0% ()
Market Cap *

$4,836 m

EPS *

$-4.6

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Apellis Pharmaceuticals IncCytomX Therapeutics IncAclaris Therapeutics Inc
Key Information
Headquarters United States of America United States of America United States of America
Headquarter City WALTHAM SOUTH SAN FRANCISCO WAYNE
Headquarter State/Province Massachusetts California Pennsylvania
No. of Employees 445 144 60
Entity Type Public Public Public

Products & Services

Apellis Pharmaceuticals operates as a clinical-stage bio-pharmaceutical company. The key products under development offered by the company include the following:

Products
  • APL-2
  • Geographic Atrophy (GA)
  • Wet Age-related Macular Degeneration (AMD)
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero

Employees

Name Position Board Since Age Biography
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2021 Contracts/Agreements In June, the company and Beam Therapeutics Inc entered into a research collaboration for the…
2020 Contracts/Agreements In October, the company entered into a strategic collaboration with Swedish Orphan Biovitrum for the…
2019 Contracts/Agreements In February, the company and SFJ Pharmaceuticals entered into an agreement to support the development…
2018 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2017 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2017 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


Potentia Pharmaceuticals Inc

Address

Suite A, 6400 Westwind Way, Crestwood
United States of America

Telephone

1 502 2414114

Website

www.potentiapharma.com

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
10 Aug 2021 Apellis Pharmaceuticals Enters Manufacturing Agreement with Emergent BioSolutions for Empaveli Contract Service Agreement Apellis Pharmaceuticals Inc Emergent BioSolutions Inc
10 Aug 2021 Apellis Pharmaceuticals Enters Manufacturing Agreement with Juzen Chemical for Empaveli Contract Service Agreement Apellis Pharmaceuticals Inc Juzen Chemical Corp
30 Jun 2021 Apellis Pharma Enters into Licensing Agreement with Beam Therapeutics Licensing Agreement Apellis Pharmaceuticals Inc Beam Therapeutics Inc
27 Oct 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
28 May 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
06 May 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

56

Active Jobs

21

Posted

18

Closed

Job Trends

Latest Jobs

Job title Company Country
Senior Manager Global Trade Compliance Apellis Pharmaceuticals Inc United States
Associate Director - GMP Quality Assurance Apellis Pharmaceuticals Inc United States
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar